Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT05691517RecruitingPhase 1
Test drug CBX-12 in advanced cancers and monitor your response
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
Bethesda, MarylandAges 18 years+ - NCT04879121RecruitingPhase 2
Larotrectinib for tumors with extra NTRK gene copies
This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.
Houston, TexasAges 16 years+ - NCT06741644RecruitingPhase 1/Phase 2
CS2009 for advanced solid tumors
This trial tests a new drug called CS2009 for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06635785RecruitingPhase 1/Phase 2
AI-081 for advanced solid tumors
This trial tests a new drug called AI-081 that targets the immune system and tumor blood vessels. It is for people with advanced solid tumors who have not responded to other treatments or cannot take them.
Birmingham, AlabamaAges 18 years+ - NCT06260514RecruitingPhase 1
New drug APR-1051 for advanced solid tumors
This trial tests a new drug called APR-1051 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and effective.
Houston, TexasAges 18 years+ - NCT06657222RecruitingPhase 1/Phase 2
Study of TUB-030 for advanced solid tumors
This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT07622524RecruitingPhase 1
Testing CS5007 for Advanced Solid Tumors
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
Darlinghurst, New South WalesAges 18 years+ - NCT07266428RecruitingPhase 1/Phase 2
Study of a new drug (OTP-01) for advanced solid tumors
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT06167317RecruitingPhase 1
Study of GS-0201 alone and combined for advanced solid tumors
This trial tests a new drug called GS-0201, either by itself or with other treatments, for people with advanced solid tumors. The goal is to see if it is safe and helpful.
Boston, MassachusettsAges 18 years+ - NCT05272709RecruitingPhase 1/Phase 2
New pill TT-702 for advanced solid tumors
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
LondonAges 16 years+ - NCT06990698RecruitingPhase 1
Testing FP008 in advanced solid tumors
This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.
Wuhan, HubeiAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT06598800RecruitingPhase 1
Study of BG-T187 alone or with other drugs for advanced solid tumors
This trial tests a new treatment, BG-T187, given alone or with other medicines for people with advanced solid tumors that have spread or cannot be removed. It is for those who have already tried other treatments.
Hackensack, New JerseyAges 18 years+ - NCT06258408RecruitingPhase 1
BB102 for advanced solid tumors that have not responded to treatment
This trial studies a new drug called BB102 that targets a specific protein (FGF19/FGFR4) found on some cancer cells. It is for people with advanced solid tumors, especially liver cancer, who have run out of standard treatment options. The goal is to see if the drug is safe and helps shrink or control the cancer.
Guangzhou, GuangdongAges 18–78 - NCT07749586RecruitingPhase 1/Phase 2
Study of ARV-6723 alone or with pembrolizumab for advanced solid tumors
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
Huntersville, North CarolinaAges 18 years+ - NCT06632574RecruitingPhase 1
Paclitaxel liposomes via artery for advanced solid tumors
This trial tests a new form of paclitaxel (a chemotherapy drug) wrapped in tiny fat bubbles called liposomes. It is given directly into an artery that feeds the tumor, which may deliver the drug more effectively to the cancer. The study is for people with advanced solid tumors that can be treated this way, such as stomach, liver, pancreatic, or lung cancers.
NanjingAges 18 years+ - NCT06694480RecruitingPhase 1
Study of FID-022 for advanced solid tumors
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
Los Angeles, CaliforniaAges 18 years+ - NCT06439589RecruitingPhase 1/Phase 2
Drug combo for advanced solid tumors
This trial tests a new combination of two drugs (HRS2398 and Adebrelimab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Zhengzhou, HenanAges 18–75 - NCT06426680RecruitingPhase 1
Study of ILB-3101 for advanced solid tumors
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
ShanghaiAges 18–80 - NCT06384352RecruitingPhase 1
Study of YL211 for advanced solid tumors
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
Aurora, ColoradoAges 18 years+ - NCT06400485RecruitingEarly Phase 1
Testing AMT-676 for advanced solid tumors
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
Huntersville, North CarolinaAges 18 years+ - NCT06470971RecruitingPhase 2
Siltuximab to prevent severe side effects during immunotherapy rechallenge
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Columbus, OhioAges 18 years+ - NCT06431243RecruitingPhase 1/Phase 2
Purinostat Mesylate for advanced solid tumors
This trial tests a new drug called Purinostat Mesylate, either alone or combined with other drugs, in people with advanced solid tumors (including breast cancer) that have not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
Guanzhou, GuangzhouAges 18–75
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,322 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.